EUVIMEDEUVIMED entdecken
Vergleichsstudie

Clinical performance of [68Ga]Ga-DOTA-FAPI-04 PET/CT in detecting recurrent disease in medullary thyroid carcinoma: a comparative analysis with [18F]F-FDG and [68Ga]Ga-DOTATATE PET/CT, alongside identification of suitable candidates for targeted radionuclide therapy

Shyam Kumar Ravada, Rahul Vithalrao Parghane, Anuja Deshmukh, Minit Shah, Gouri Pantvaidya, Sandip Basu

European Journal of Nuclear Medicine and Molecular Imaging · 2026

DOI: 10.1007/s00259-026-08031-w ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Shyam Kumar Ravada und 5 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Jerbai Wadia Road, Parel, 400 012, Mumbai, India. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Thyroid Neoplasms, Fluorodeoxyglucose F18, Organometallic Compounds. Die Arbeit nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIM: To evaluate and compare the diagnostic performance of [68Ga]Ga-DOTA-FAPI-04 with [18F]F-FDG and [68Ga]Ga-DOTATATE PET/CT for detecting recurrent disease in patients with medullary thyroid carcinoma (MTC) and additionally evaluate their role for prognostication and theranostics in management of MTC. METHODS: In this prospective single-centre study, 56 patients with suspected recurrent MTC underwent [68Ga]Ga-DOTA-Fibroblast activation protein inhibitor (FAPI)-04, [18F]F-FDG, and [68Ga]Ga-DOTATATE PET/CT. The primary endpoint was patient-based diagnostic accuracy for recurrent disease. Secondary endpoints included lesion-based detection rates across pre-defined anatomical regions, correlation with biochemical and clinicopathological parameters, prognostic assessment for progression-free survival, and a novel exploratory FAPI-SSTR Theranostic (FAST) score was developed to guide personalized radiopharmaceutical therapy (RPT). RESULTS: [68Ga]Ga-DOTA-FAPI-04 PET/CT demonstrated higher sensitivity 95.92% and accuracy 94.64% compared to [18F]F-FDG-PET/CT (sensitivity: 89.80%, accuracy: 89.29%) and [68Ga]Ga-DOTATATE (sensitivity: 77.55%, accuracy: 76.79%) on patient-based analysis for detecting recurrent disease. [68Ga]Ga-DOTA-FAPI-04 was showed high detection rates for disease recurrence in mediastinal nodal (91.9%), liver (91.7%), and skeletal (86.5%) metastases.[68Ga]Ga-DOTA-FAPI-04 uptake was associated with a modestly shorter mean progression-free survival and altered clinical management in 35.7% of total patients. Additionally, the pre-defined exploratory FAST scoring system stratified 34 patients (60.7%) for [177Lu]Lu-FAPI-RPT, 8 (14.3%) for [177Lu]Lu-DOTATATE PRRT, and 9 (16.1%) for either or combined RPT. CONCLUSION: [68Ga]Ga-DOTA-FAPI-04 PET/CT showed higher diagnostic accuracy for the identification of recurrent MTC over standard [18F]F-FDG and [68Ga]Ga-DOTATATE PET/CT, with higher regional detection rates for liver and osteoblastic skeletal metastases. Furthermore, while the exploratory FAST score provides a framework for patient stratification and personalizing targeted theranostic strategies, it requires future validation through larger multicentre trials prior to clinical adoption.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyThyroid NeoplasmsFluorodeoxyglucose F18Organometallic CompoundsCarcinoma, NeuroendocrineHumansFemaleMaleMiddle AgedAdultAgedFibroblast Activation Protein AlphaRecurrenceNeoplasm Recurrence, LocalRadiopharmaceuticalsQuinolines

Stichwörter der Autor:innen

FAPI-SSTR Theranostic (FAST) score TheranosticsFibroblast activation protein inhibitor (FAPI)Medullary thyroid carcinoma (MTC)[177Lu]Lu-FAPI radiopharmaceutical therapy[18F]F-FDG PET/CT[68Ga]Ga-DOTATATE PET/CT[68Ga]Ga-FAPI-04 PET/CT

Substanzen

Fluorodeoxyglucose F18Organometallic Compoundsgallium Ga 68 dotatateFibroblast Activation Protein Alpha68Ga-FAPIRadiopharmaceuticalsQuinolines

Autor:innen und Institutionen

  • Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Jerbai Wadia Road, Parel, 400 012, Mumbai, India.
  • Homi Bhabha National Institute, Mumbai, India.
  • Department of Surgical Oncology, Tata Memorial Centre, Parel, Mumbai, 400 012, India.
  • Department of Medical Oncology, Tata Memorial Centre, Parel, Mumbai, 400 012, India.
  • Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Jerbai Wadia Road, Parel, 400 012, Mumbai, India. drsanb@yahoo.com.
  • Homi Bhabha National Institute, Mumbai, India. drsanb@yahoo.com.

Zitieren

APA

Ravada, S. K., Parghane, R. V., Deshmukh, A., Shah, M., Pantvaidya, G., & Basu, S. (2026). Clinical performance of [68Ga]Ga-DOTA-FAPI-04 PET/CT in detecting recurrent disease in medullary thyroid carcinoma: a comparative analysis with [18F]F-FDG and [68Ga]Ga-DOTATATE PET/CT, alongside identification of suitable candidates for targeted radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08031-w

Vancouver

Ravada SK, Parghane RV, Deshmukh A, Shah M, Pantvaidya G, Basu S. Clinical performance of [68Ga]Ga-DOTA-FAPI-04 PET/CT in detecting recurrent disease in medullary thyroid carcinoma: a comparative analysis with [18F]F-FDG and [68Ga]Ga-DOTATATE PET/CT, alongside identification of suitable candidates for targeted radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-026-08031-w

BibTeX
@article{Ravada2026,
  author = {Ravada, Shyam Kumar and Parghane, Rahul Vithalrao and Deshmukh, Anuja and Shah, Minit and Pantvaidya, Gouri and Basu, Sandip},
  title = {Clinical performance of [68Ga]Ga-DOTA-FAPI-04 PET/CT in detecting recurrent disease in medullary thyroid carcinoma: a comparative analysis with [18F]F-FDG and [68Ga]Ga-DOTATATE PET/CT, alongside identification of suitable candidates for targeted radionuclide therapy},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  doi = {10.1007/s00259-026-08031-w}
}
Kostenlos starten →